Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Liraglutide
Therapeutic Area : Musculoskeletal
Study Phase : Phase I
Sponsor : French Government
Deal Size : $8.3 million
Deal Type : Funding
4Moving Biotech Wins €7.6M Grant For Osteoarthritis Drug Innovation
Details : The funding aims to advance the clinical dvelopment of company's lead product 4P004 (liraglutide), which is being evaluated for the treatment of knee osteoarthritis.
Product Name : 4P004
Product Type : Peptide
Upfront Cash : Undisclosed
April 07, 2025
Lead Product(s) : Liraglutide
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I
Sponsor : French Government
Deal Size : $8.3 million
Deal Type : Funding
Lead Product(s) : Liraglutide
Therapeutic Area : Musculoskeletal
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
4Moving Biotech Announces Success in Phase I Trial of Liraglutide for Knee Osteoarthritis
Details : 4P004 (intraarticular liraglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist, which is indicated for the treatment of patients with knee osteoarthritis.
Product Name : 4P004
Product Type : Peptide
Upfront Cash : Inapplicable
October 06, 2024
Lead Product(s) : Liraglutide
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Liraglutide
Therapeutic Area : Musculoskeletal
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : 4P004, a GLP1 analog, is a novel first-in-class drug candidate addressing a high unmet medical need. The purpose is to potentially change the natural course of osteoarthritis to prevent long-term disability.
Product Name : 4P004
Product Type : Peptide
Upfront Cash : Inapplicable
October 19, 2023
Lead Product(s) : Liraglutide
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Liraglutide
Therapeutic Area : Musculoskeletal
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
4Moving Biotech Announces First Patient Enrolled in Phase I Clinical Trial on Osteoarthritis
Details : 4P004 is a novel first-in-class drug candidate addressing a high unmet medical need that is the absence of a curative treatment for osteoarthritis. 4P004 is a disease-modifying OA drug (DMOAD) candidate.
Product Name : 4P004
Product Type : Peptide
Upfront Cash : Inapplicable
October 14, 2022
Lead Product(s) : Liraglutide
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable